Updates in Immunotherapy for Pancreatic Cancer

被引:0
|
作者
Chick, Robert Connor [1 ]
Pawlik, Timothy M. [1 ]
机构
[1] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
pancreatic cancer; immunotherapy; personalized; tumor microenvironment; immune checkpoint inhibitor; cancer vaccine; T-CELLS; TUMOR MICROENVIRONMENT; CHECKPOINT INHIBITORS; STROMAL INFLAMMATION; NEOADJUVANT THERAPY; OPEN-LABEL; COMBINATION; TRIAL; PEMBROLIZUMAB; FOLFIRINOX;
D O I
10.3390/jcm13216419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit a dysregulated host immune response, PDAC is often characterized by poor immune infiltration and an immune-privileged fibrotic stroma. As understanding of the tumor microenvironment (TME) evolves, novel therapies are being developed to target immunosuppressive mechanisms. Immune checkpoint inhibitors have limited efficacy when used alone or with radiation. Combinations of immune therapies, along with chemotherapy or chemoradiation, have demonstrated promise in preclinical and early clinical trials. Despite dismal response rates for immunotherapy for metastatic PDAC, response rates with neoadjuvant immunotherapy are somewhat encouraging, suggesting that incorporation of immunotherapy in the treatment of PDAC should be earlier in the disease course. Precision therapy for PDAC may be informed by advances in transcriptomic sequencing that can identify immunophenotypes, allowing for more appropriate treatment selection for each individual patient. Personalized and antigen-specific therapies are an increasing topic of interest, including adjuvant immunotherapy using personalized mRNA vaccines to prevent recurrence. Further development of personalized immune therapies will need to balance precision with generalizability and cost.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Clinical immunotherapy in pancreatic cancer
    Xiaorong Ye
    Yue Yu
    Xiaohu Zheng
    Hongdi Ma
    Cancer Immunology, Immunotherapy, 73
  • [22] Towards immunotherapy of pancreatic cancer
    McKenzie, IFC
    Apostolopoulos, V
    GUT, 1999, 44 (06) : 767 - 769
  • [23] Recent updates on the role of chemotherapy in pancreatic cancer
    Burris, HA
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S1 - S3
  • [24] Therapeutic Approaches in Pancreatic Cancer: Recent Updates
    Kumar, Lokender
    Kumar, Sanjay
    Sandeep, Kumar
    Patel, Sanjay Kumar Singh
    BIOMEDICINES, 2023, 11 (06)
  • [25] Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
    Li, Zihai
    Song, Wenru
    Rubinstein, Mark
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [26] The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer
    Chen, Shiu-Jau
    Wang, Shao-Cheng
    Chen, Yuan-Chuan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [27] Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
    Zihai Li
    Wenru Song
    Mark Rubinstein
    Delong Liu
    Journal of Hematology & Oncology, 11
  • [28] Pancreatic Cancer: New Approach for Immunotherapy
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (08): : 726 - +
  • [29] Is immunotherapy the holy grail for pancreatic cancer?
    Andersson, Roland
    Pereira, Carlos-Filipe
    Bauden, Monika
    Ansari, Daniel
    IMMUNOTHERAPY, 2019, 11 (17) : 1435 - 1438
  • [30] Dilemma and Challenge of Immunotherapy for Pancreatic Cancer
    Wu, Jia
    Cai, Jianting
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (02) : 359 - 368